Eczeva Supplementation and Skin Health
NCT07049770 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2025-07-03
Summary
Eczema, also known as atopic dermatitis, is a chronic skin condition characterized by inflamed, itchy, and often dry skin. It commonly affects individuals of all ages, although it frequently begins during childhood. The causes of eczema are multifactorial, including genetic, immune, and environmental factors. Genetic mutations, such as those in the FLG gene responsible for producing filaggrin, a protein vital to skin barrier function, play a significant role (1). Immune system dysregulation, particularly an overactive response to environmental allergens, also contributes to eczema (2). Environmental triggers are diverse and include irritants like soaps, detergents, and disinfectants, as well as allergens such as pollen, pet dander, dust mites, mold, and certain foods (3-8). Climatic conditions, such as cold or dry air, and high humidity, can exacerbate symptoms, as can exposure to air pollution and chlorinated water in swimming pools (3-8). Specific skincare products containing allergens or irritants may worsen the condition. Other factors influencing eczema include infections (bacterial, viral, or fungal) (9), dietary triggers like dairy, nuts, eggs, and soy (10), and clothing choices, with materials like wool and synthetics or tight-fitting clothes aggravating symptoms through skin irritation and friction (11, 12).
Individuals with certain habits or characteristics are at a higher risk of developing eczema. A family history of eczema, asthma, or hay fever significantly increases the likelihood of the condition, as it suggests a genetic predisposition (13). Emotional stress and anxiety are known to trigger or worsen eczema symptoms (14), as are hormonal changes during pregnancy or menstruation, which can cause flare-ups (15). People who sweat excessively may experience irritation and aggravation of eczema, as the moisture can exacerbate inflammation (16). Smoking or exposure to cigarette smoke is another contributing factor, known to both trigger and worsen eczema (17). Those working in professions with frequent exposure to irritants or allergens, such as healthcare or cleaning, are at higher risk due to contact with harsh chemicals (18). Additionally, excessive hand washing can strip the skin of its natural moisture, leading to irritation and exacerbating eczema symptoms (18).
The main active ingredient in Eczeva is Melicope ptelefolia. Melicope ptelefolia, commonly known as Tenggek Burung, has been used for centuries in traditional herbal medicine to treat various skin conditions, including wounds, itches, and skin diseases (19). The plant is known for its high content of bioactive compounds, particularly 2,4,6-trihydroxy-3-geranyl acetophenone (tHGA) and 2,4,6-trihydroxy-3-prenyl acetophenone (tHPA). Among these, tHGA has shown significant potential due to its inhibitory effects on lipoxygenase (LOX) activity, suggesting its anti-inflammatory properties that may help in treating conditions like eczema (20). An in vitro study demonstrated that tHGA reduced inflammatory markers and enhanced the integrity of the skin barrier, both of which are crucial for managing inflammation-related conditions like eczema (21). Further research also indicated that tHGA could improve epithelial barrier function and reduce cell permeability in inflamed tissues, a key factor in treating eczema, which is characterized by an impaired skin barrier function (22). These findings highlight the therapeutic potential of Melicope ptelefolia in managing eczema through its anti-inflammatory and barrier-strengthening effects.
Research on the efficacy of Melicope ptelefolia supplements in improving skin health in human is remain largely unexplored. This study aims to determine the mechanism and effects of Eczeva supplements on improving the skin health among users.
Conditions
- Skin
- Eczema
Interventions
- DIETARY_SUPPLEMENT
-
Eczeva supplementation
Intervention contains 0.2g of eczefolia extracts, and 0.01g of rice ceramides as main active ingredients.
Sponsors & Collaborators
-
UCSI University
collaborator OTHER -
Zest Healthtech PLT
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-01
- Primary Completion
- 2025-02-28
- Completion
- 2025-05-31
Countries
- Malaysia
More Related Trials
-
Management of Pruritus With Xyzal in Atopic Dermatitis
NCT00884325 ·Status: COMPLETED ·Phase: PHASE4
-
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
NCT06144424 ·Status: COMPLETED ·Phase: PHASE2
-
Investigating Immune Mechanisms in Atopic Eczema
NCT02102841 ·Status: WITHDRAWN ·Phase: NA
-
Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis
NCT04413942 ·Status: UNKNOWN ·Phase: PHASE2
-
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis
NCT06487000 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Pilot Study of Efficacy and Safety of SIM05 in Adults With Atopic Eczema
NCT06230991 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07006792 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Identifying Risk Factors for Eczema Herpeticum in Individuals With Atopic Dermatitis
NCT00438022 ·Status: COMPLETED
-
Role of Anti-IgE in Severe Childhood Eczema
NCT02300701 ·Status: COMPLETED ·Phase: PHASE4
-
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Effects of a Botanical Moisturizer and an Unscented Soap on Eczema and Itch
NCT06804070 ·Status: COMPLETED ·Phase: NA
-
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT00605878 ·Status: RECRUITING
-
Skin Microbial Ecology in Atopic Dermatitis
NCT04170244 ·Status: RECRUITING
-
A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
NCT07193589 ·Status: RECRUITING ·Phase: PHASE2
-
The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema
NCT05003453 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
NCT07216027 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Dietary Intervention on Atopy
NCT06547372 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
NCT04871711 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis
NCT01065714 ·Status: COMPLETED ·Phase: PHASE4
-
Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective
NCT07323394 ·Status: NOT_YET_RECRUITING
-
Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels
NCT00616096 ·Status: COMPLETED ·Phase: NA
-
Efalizumab for Moderate to Severe Atopic Dermatitis
NCT00226057 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area
NCT05226143 ·Status: COMPLETED ·Phase: NA
-
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.
NCT06756438 ·Status: RECRUITING ·Phase: NA